Skip to main content
SpringerLink
Log in

Abiraterone Acetate Therapy for mCRPC in Japanese Men

  • Chapter
  • First Online:
Hormone Therapy and Castration Resistance of Prostate Cancer

  • 579 Accesses

Abstract

Abiraterone acetate (AA) is a first-in-class CYP17 (17α-hydroxylase/C17, 20 lyase) inhibitor that is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). AA prolonged overall survival in both mCRPC patients with or without previously chemotherapy by two randomized Phase III studies (COU-AA-301 and 302 trial). In Japan, AA approved in 2014, similar efficacy and safety of AA are demonstrated. Prostate-specific antigen (PSA) response rates were 60.4% in chemotherapy naïve mCRPC patients (JPN-201 study) and 28.3% in post-chemotherapy mCRPC patients (JPN-202 study), respectively. The most common were liver dysfunction and mineralocorticoid-related adverse events such as hypokalemia, hypertension, and edema. Majority of the adverse events were grade 1 or 2 in severity. PSA flare phenomenon observed approximately 10% during AA treatment, which is feature and different from that of enzalutamide. There is no clear answer to sequential androgen receptor-axis-targeted therapy. But, AA to enzalutamide sequence may be better outcome for PSA progression-free survival compared with reverse sequence. Even in elderly patients with mCRPC, if the patients can be treated, they can be safe and obtain the sufficient therapeutic effect. However, there is no report of AA treatment in Japanese elderly mCRPC patients. This review evaluated the use of AA for Japanese mCRPC patients in detail.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. O’Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90(12):2317–25. https://doi.org/10.1038/sj.bjc.6601879.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011;17(14):4854–61. https://doi.org/10.1158/1078-0432.CCR-11-0815.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28(9):1496–501. https://doi.org/10.1200/JCO.2009.25.9259.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, Investigators CA. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. https://doi.org/10.1056/NEJMoa1014618.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Matsubara N, Uemura H, Satoh T, Suzuki H, Nishiyama T, Uemura H, Hashine K, Imanaka K, Ozono S, Akaza H. A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). Jpn J Clin Oncol. 2014;44(12):1216–26. https://doi.org/10.1093/jjco/hyu149.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, Investigators CA. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48. https://doi.org/10.1056/NEJMoa1209096.

    Article  CAS  PubMed  Google Scholar 

  7. Miyake H, Hara T, Terakawa T, Ozono S, Fujisawa M. Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naive metastatic castration-resistant prostate cancer: experience in real-world clinical practice in Japan. Clin Genitourin Cancer. 2017;15(2):313–9. https://doi.org/10.1016/j.clgc.2016.06.010.

    Article  PubMed  Google Scholar 

  8. Satoh T, Uemura H, Tanabe K, Nishiyama T, Terai A, Yokomizo A, Nakatani T, Imanaka K, Ozono S, Akaza H. A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy. Jpn J Clin Oncol. 2014;44(12):1206–15. https://doi.org/10.1093/jjco/hyu148.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Angelergues A, Maillet D, Flechon A, Ozguroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, Fizazi K, de La Motte Rouge T, Delanoy N, Elaidi RT, Oudard S. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. Eur J Cancer. 2014;50(9):1602–9. https://doi.org/10.1016/j.ejca.2014.03.015.

    Article  CAS  PubMed  Google Scholar 

  10. Burgio SL, Conteduca V, Rudnas B, Carrozza F, Campadelli E, Bianchi E, Fabbri P, Montanari M, Carretta E, Menna C, De Giorgi U. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(1):39–43. https://doi.org/10.1016/j.clgc.2014.06.010.

    Article  PubMed  Google Scholar 

  11. Narmala SK, Boulmay BC. PSA flare after initiation of abiraterone acetate. J Community Support Oncol. 2014;12(5):191–2.

    Article  PubMed  Google Scholar 

  12. Ueda Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H. Prostate-specific antigen flare phenomenon induced by abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2017;15(2):320–5. https://doi.org/10.1016/j.clgc.2016.07.026.

    Article  PubMed  Google Scholar 

  13. Maughan BL, Luber B, Nadal R, Antonarakis ES. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. Prostate. 2017;77(1):33–40. https://doi.org/10.1002/pros.23246.

    Article  CAS  PubMed  Google Scholar 

  14. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7):1802–7. https://doi.org/10.1093/annonc/mdt138.

    Article  CAS  PubMed  Google Scholar 

  15. Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol. 2015;67(1):23–9. https://doi.org/10.1016/j.eururo.2014.06.045.

    Article  CAS  PubMed  Google Scholar 

  16. Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2017;15(4):e591–7. https://doi.org/10.1016/j.clgc.2016.12.015.

    Article  PubMed  Google Scholar 

  17. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36(4):453–71.

    Article  CAS  PubMed  Google Scholar 

  18. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16(5):622–6.

    Article  CAS  PubMed  Google Scholar 

  19. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.

    Article  CAS  PubMed  Google Scholar 

  20. Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, Kattan MW, Monfardini S, Moul JW, Naeim A, van Poppel H, Saad F, Sternberg CN. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int. 2010;106(4):462–9. https://doi.org/10.1111/j.1464-410X.2010.09334.x.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, Kheoh T, Griffin TW, Molina A, Ryan CJ. Efficacy and safety of abiraterone acetate in elderly (75 years or older) chemotherapy naive patients with metastatic castration resistant prostate cancer. J Urol. 2015;194(5):1277–84. https://doi.org/10.1016/j.juro.2015.07.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

    Masaomi Ikeda M.D., Ph.D. & Takefumi Satoh M.D., Ph.D.

  2. Takefumi Satoh Prostate Clinic, Tokyo, Japan

    Takefumi Satoh M.D., Ph.D.

Authors
  1. Masaomi Ikeda M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takefumi Satoh M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaomi Ikeda M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Urology, Tohoku University School of Medicine, Sendai, Japan

    Yoichi Arai

  2. Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Osamu Ogawa

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ikeda, M., Satoh, T. (2018). Abiraterone Acetate Therapy for mCRPC in Japanese Men. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_25

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7013-6_25

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7012-9

  • Online ISBN: 978-981-10-7013-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation